Established in 2001, listed on Shanghai Stock Exchange, China (Stock code: 688580)
Quick growth driven by technology innovations
Core competence built on proprietary intellectual properties (IP)
Innovative products/solutions based on core IP and technology platforms:
√ Magnetic Stimulation (TMS, FMS and PMS)
√ Rehab Robotics
√ E-stim (electrical stimulation)
√ Electrophysiology
Full name | Nanjing Vishee Medical Technology Co., Ltd. |
---|---|
Abbreviations | VISHEE |
Code | 688580 |
Founded | 2001-01-10 |
Listing | 2020-07-21 |
Domicile | Nanjing |
ir@vishee.com | |
STAR Theme | Biomedicine |
CSRC Sector | Manufacturing |
Has weighted voting rights structure? | No |
2020 | 2019 | 2018 | |
---|---|---|---|
Earnings Per Share | 2.46 | 1.95 | 1.24 |
R&D expenditure as a % of operating revenue | 9.06% | 8.59% | 8.92% |
Operating Revenue | 378.37 | 318.87 | 207.78 |
Net Income | 143.13 | 98.89 | 62.72 |
2020 | 2019 | 2018 | |
---|---|---|---|
Operating Revenue | 378.37 | 318.87 | 207.78 |
Operating Costs | 99.76 | 83.82 | 53.68 |
Operating Income | 164.86 | 114.67 | 72.02 |
Pretax Income | 166.08 | 114.80 | 73.36 |
Income Tax | 22.95 | 15.91 | 10.64 |
Net Income | 143.13 | 98.89 | 62.72 |
2020 | 2019 | 2018 | |
---|---|---|---|
Assets | |||
Current Assets-Total | 1,418.87 | 282.31 | 185.42 |
Non-current Assets-Total | 121.57 | 121.91 | 122.94 |
Total Assets | 1,540.44 | 404.22 | 308.36 |
Liabilities | |||
Current Liabilities-Total | 128.68 | 141.64 | 94.51 |
Non-current Liabilities-Total | 0.78 | 7.72 | 17.69 |
Total Liabilities | 129.45 | 149.35 | 112.20 |
Stockholder's Equity | |||
Share Capital | 1,133.53 | 70.56 | 70.63 |
Retained Profits | 272.49 | 178.69 | 116.80 |
Minority Interests | 4.97 | 5.62 | 8.73 |
Total Owners' Equity | 1,410.99 | 254.86 | 196.16 |
2020 | 2019 | 2018 | |
---|---|---|---|
Net Cash Flows-Operating | 120.76 | 141.47 | 85.84 |
Net Cash Flows-Investing | 1.85 | -16.90 | -37.55 |
Net Cash Flows-Financing | 994.76 | -42.45 | -21.49 |
Name | No. of Shares Held (mn) | % of Shares Held |
---|---|---|
王志愚 | 26.96 | 39.45% |
胡平 | 11.23 | 16.43% |
南京志达投资管理咨询中心(有限合伙) | 5.67 | 8.29% |
深圳市阳和生物医药产业投资有限公司 | 3.51 | 5.13% |
南京志明达企业管理咨询中心(有限合伙) | 1.26 | 1.84% |
张展 | 1.00 | 1.46% |
中国银行股份有限公司-广发医疗保健股票型证券投资基金 | 0.77 | 1.13% |
长江证券创新投资(湖北)有限公司 | 0.68 | 1.00% |
JPMORGAN CHASE BANK,NATIONAL ASSOCIATION | 0.59 | 0.86% |
交通银行股份有限公司-宝盈现代服务业混合型证券投资基金 | 0.46 | 0.67% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.